Virginia’s New Pharma Hub Secures $16 Million Federal Boost to Accelerate Domestic Medicine Production

On July 20, 2026, federal officials announced a $16 million infusion of money into a home‑grown pharmaceutical cluster that stretches from Petersburg’s industrial park up to Richmond’s university campus. The award, coming from the U.S. Economic Development Administration’s Regional Technology and Innovation Hubs program, is being funneled to the Virginia Advanced Pharma Manufacturing and R&D Cluster, which is overseen by the Virginia Biotechnology Research Partnership Authority.

Senators Mark Warner and Tim Kaine, together with Representative Jennifer McClellan, hailed the grant as a vital step toward “establishing a domestic manufacturing pathway for essential medicines” and bolstering national security. Their statements, delivered in a joint press release, emphasized that the funding will create good‑paying jobs in Petersburg while reducing America’s dependence on overseas drug supplies.

The cluster’s manufacturing arm is anchored in an industrial park just off I‑95 and Wagner Road in Petersburg. Early tenants include global players such as Novo Nordisk, Phlow Corp., and Civica Rx, all of which are setting up production lines for biologics and specialty drugs. Meanwhile, the research side is blossoming in Richmond, where Virginia Commonwealth University partners with the Virginia Community College System and several other state universities to drive innovation and workforce training.

Officials say the grant will fund new clean‑room facilities, state‑of‑the‑art pilot lines, and a curriculum that prepares the next generation of pharma technicians and scientists. In the words of Senator Warner, “These federal dollars will help cement the Commonwealth’s position as a national leader in advanced pharmaceutical manufacturing.” Representative McClellan added that the investment is essential for keeping the United States competitive on the global stage.

While the $16 million figure is confirmed, the specifics of the award—such as the exact distribution between manufacturing and research components—are still being worked out with the EDA. Likewise, the companies listed as tenants have announced plans publicly, but independent verification of their facility footprints will follow in the coming weeks.

What is clear, however, is that Virginia is positioning itself as a strategic hub for life‑saving medicines, hoping to turn the Commonwealth into a model for other states seeking to rebuild domestic drug‑manufacturing capacity.